Recapitalization Will Accelerate Strategic Growth to Help Sponsors Save and Improve the Lives of Patients
Investment Will Enable Veristat to Further Enhance its Market Leadership Position and Provide Resources for Growth
Veristat, a leading Clinical Research Organization (CRO) announced today that Variance Development Partners, a private investment group focused on contributing growth capital to small to mid-sized firms providing services to developing pharmaceutical and medical device companies, has made a growth equity investment in the company.